Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- BRAF V600E Mutation Positive
- Thyroid Cancer
- Thyroid Cancer (Follicular Cell)
- Thyroid Cancer, Follicular
- Thyroid Cancer, Papillary
- Thyroid Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04462471
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Alan L Ho, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon